Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma

NCT04257578 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04257578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04257578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 2, 2020
Completion date
March 1, 2031
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, diffuse large b-cell lymphoma, not otherwise specified, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, high grade b-cell lymphoma, primary mediastinal (thymic) large b-cell lymphoma, transformed follicular lymphoma to diffuse large b-cell lymphoma